Kornimate/medical-research-clean huggingface dataset:
genomic analysis of pediatric bone tumors

Conditions: Bone Cancer

Summary: to determine whether gene expression analysis of primary tumor samples before and after chemotherapy are predictive of long-term survival in pediatric patients with bone sarcomas (ewings sarcoma (es) and osteosarcoma(os)).


Eligibility criteria:
inclusion criteria:all patients with bone x-rays suggestive of a malignant bone tumor exclusion criteria:patients with a known diagnosis of cancer.
testing digital breast tomosynthesis vs. regular mammogram in detecting breast cancer in women having screening mammogram

Conditions: Breast Cancer

Summary: to compare dbt and ffdm for screening effectiveness in women who present for screening mammography with respect to screening recall rate.


Eligibility criteria:
inclusion criteria: * women ≥18 years or older for screening mammography * able and willing to comply with study procedures, and have signed and dated the informed consent form * the subject is surgically sterile or postmenopausal exclusion criteria: * pregnant or trying to become pregnant * has signs or symptoms of breast cancer * has been previously included in this study * has breast implants * has a history of breast cancer and is in active treatment * has breasts too large to be adequately positioned for the dbt examination

Keywords: mammography mammogram breast abnormal and normal breast tissue
pilot study to assess performance and safety of sulfex 13081.22 nasal spray in patients with dry or irritated nose

Conditions: Dry Nose; Nose Irritation

Summary: as the medical device is ce marked, the objective of this study is to provide performance and safety data on sulfex 13081.22 nasal spray as close as possible to the routine care.

every day, people breathe large amounts of air which contain all kinds of particles. nasal cavities are the first site of airway protection against airborne particles. the mucociliary apparatus (a layer of tiny moving hairs and mucus which covers the mucous membrane inside the nose) is the first line of defence of the upper airways and helps to eliminate these particles. if this defence mechanism is altered, it may cause nasosinusal damage or irritation and be unable to protect the respiratory system. moreover, external factors such as pollution or dry air may affect the function of the nose. the same is true for chronic and/or recurrent infections. these various factors can cause irritation or dryness of the nasal mucosa, often causing inflammation with feelings of congestion, discomfort or burning of the nasal mucosa, sometimes with bleeding or painful crusting. sulfex 13081.22 is a nasal spray, ce marked and commercialized since 2014. sulfex spray soothes, restores and provides long-lasting/intense hydration of uncomfortable, painful or sore nasal mucosa caused by excessive dryness. it also contributes towards cell regeneration for faster healing and optimum relief and protects against new external attacks.the anti-reflux valve system prevents any contamination of the solution, even after the bottle has been opened, which means the formula remains 100% aseptic. as the medical device is ce marked, the objective of this study is to provide performance and safety data on sulfex 13081.22 nasal spray as close as possible to the routine care.

Eligibility criteria:
inclusion criteria: * patient \> 18 years of age. * patient voluntarily buying the spray and using it for him/herself. * patient with nasal dryness and/or nasal irritation. * patient informed of the study, who gave its express consent (free, informed, written) before any specific procedure to the study. * patient meeting study's requirements regarding follow-up schedule and questionnaires filling. * patient affiliated to a social security scheme. exclusion criteria: * patient currently taking corticosteroids or antibiotics or antihistamines or nonsteroidal anti-inflammatory drugs (nsaids) or topical decongestants or systemic decongestants * patient currently using other nasal sprays, nasal pumps, nasal irrigation/lavage device, or oils, creams or gels into the nose. * patient deprived of freedom or subject to legal protection measures. * pregnant or breastfeeding woman.

Keywords: nasal obstruction nasal obstruction, bilateral nasal bleeding nasal passage irritation nasal pain nasal crusting nasal itching nasal burning nasal discomfort sneezing airborne particles mucous membrane
effects of probiotic and hiit in obese women

Conditions: Cardiorespiratory Fitness; Metabolism; Anthropometry

Summary: the aim of this study is to investigate whether there are the additive effects when implementing both high-intensity interval training (hiit) and probiotics simultaneously on improving cardiorespiratory endurance and metabolism in middle-aged women.

high-intensity interval training (hiit) is a time-efficiency exercise mode that has been shown to reduce body fat, fasting blood insulin levels, arterial stiffness, and aerobic capacity, helping to prevent and improve chronic diseases. probiotics, on the other hand, have been found to have similar effects, including improving insulin sensitivity and endurance exercise performance, as well as reducing body fat. however, the additive effects of hiit combined with probiotic supplements are unclear. in addition, on average, the life expectancy of women is longer than that of men. middle-aged women are at high-risk for obesity and metabolic-related problems that threaten their long-term health. therefore, whether the combination of hiit and probiotics can be utilized to enhance the wellness of middle-aged women is the objective of this study.

Eligibility criteria:
inclusion criteria: * female * age between 35-55 years old * total body fat percentage greater than 30% exclusion criteria: * male * participants who were taking probiotics supplementation or antibiotics * percentage of total body fat less than 30%
study of montelukast on gastrointestinal tolerability in patients with relapsing forms of multiple sclerosis receiving tecfidera

Conditions: Multiple Sclerosis

Summary: the primary objective of this study is to evaluate whether montelukast can reduce the severity of gastrointestinal (gi) events, measured by the gastrointestinal symptom rating scale (gsrs), after oral administration of dimethyl fumarate (dmf) in participants with relapsing forms of multiple sclerosis (ms). the secondary objectives of this study are as follows: to evaluate whether montelukast after oral administration of dmf in participants with relapsing forms of ms decreases discontinuations due to gi events and reduces the number of participants taking symptomatic therapies for gi events; to investigate the effect of montelukast on the incidence of flushing events after oral administration of 240 mg dmf in participants with relapsing forms of ms.


Eligibility criteria:
key inclusion criteria: * reside in the united states and have a confirmed diagnosis of a relapsing form of ms and satisfy the therapeutic indication as described in the local label * as perceived by the investigator, have the ability to comply with all requirements of the study protocol and to operate the ediary required to record gi-related events * female participants of childbearing potential who are not surgically sterile must practice effective contraception during their participation in the study and be willing and able to continue contraception for 30 days after they complete or withdraw from the study. all men must practice effective contraception, and they should not donate sperm throughout the study and for at least 90 days after their last dose of study treatment. key exclusion criteria: * history of significant gi disease (for example, irritable bowel disease, peptic ulcer disease, history of major gi surgery, eosinophilic gi disease, or food allergies) * chronic use (≥7 consecutive days) of bismuth subsalicylate, simethicone, calcium carbonate, loperamide, proton-pump inhibitors, or ondansetron within 1 month prior to the screening visit * use of the following medications: montelukast, immunotherapy, mast cell stabilizers, or parenteral, inhaled, or oral steroids up to 1 month prior to the screening visit. use of these medications is also not permitted for the duration of the study (except for the use of montelukast as per study protocol) and will lead to discontinuation * have one or more major comorbidities that, in the opinion of the investigator, may affect the outcome of the study * history of malignancy (except for basal cell carcinoma that had been completely excised prior to study entry), severe allergic or anaphylactic reactions or known drug hypersensitivity, abnormal laboratory results indicative of any significant disease, and/or a major disease that would preclude participation in a clinical study note: other protocol defined inclusion/exclusion criteria may apply
ovatio dr and vr implantable cardioverter defibrillators post-approval study

Conditions: Sudden Cardiac Death

Summary: the purpose of this post-approval study is to confirm the safety and effectiveness of ovatio dr and vr icds


Eligibility criteria:
inclusion criteria: * candidates will come from the investigator's general icd population who meet any of the accepted indications for an icd implant according to the "acc/aha/esc 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death" (zipes et al., jacc vol. 48, no. 5, sept. 2006:1064-1108). exclusion criteria: * ventricular tachyarrhythmia that may have transient or reversible causes such as: acute myocardial infarction, digitalis intoxication, drowning, electrocution, electrolyte imbalance, hypoxia, sepsis, or unstable ischemic episodes * incessant tachyarrhythmia * implanted pacemaker * primary disorder of bradyarrhythmia or atrial tachyarrhythmia * of minor age * pregnant * participating in another clinical study
safety of endobronchial mesenchymal stromal cells in the treatment of chronic lung allograft dysfunction

Conditions: Chronic Lung Disease; Lung Transplant Rejection

Summary: lung transplantation is the only therapeutic alternative for more and more patients with respiratory diseases in their most advanced stages. the most limiting factor to achieve long term survival si chronic lung allograft dysfunction, a multifactorial disease without an effective treatment. the immunomodulatory capacity of mesenchymal stem cells enables them to be a potential therapeutic agent for this condition. the objective of this study is to assess the safety of endobronchial administration of allogeneic mscs in patients with chroniclung allograft dysfunction.


Eligibility criteria:
inclusion criteria: patients should have signed written informed consent. adult patients ≥18 years of age at the time of enrolment patients recipients of a uni or bipulmonary transplant an established diagnosis of bos ≧ 0p (fev1≤90% and / or fef 25-75% ≤ of the baseline value with no other justifying cause) in the last 6 months. exclusion criteria: * history of lobar transplantation history of heart-lung transplantation active infection at the time of inclusion. active acute rejection not treated at the time of inclusion. oncological history (except cutaneous basal cell or carcinoma in situ) systemic autoimmune diseases. active hiv / hbv / hcv infection (confirmed by serology or pcr) proximal airway stenosis pregnancy performance status 3 or 4 (confined to bed or chair for more than 50% of waking hours, able only to perform some self-care activities) estimated survival less than 3 months. known hypersensitivity to components used in the production of allogeneic mscs. any circumstance that, in the opinion of the investigator, compromises the patient's ability to participate in the clinical trial.
evaluating patient and physician cost knowledge in the emergency department

Conditions: Economic Problems

Summary: the purpose of this study is to identify existing cost knowledge of emergency medicine (em) physicians and patients and investigates its reported impacts on medical compliance. a cross-sectional survey will be administered electronically to emergency medicine physicians at the university of utah hospital and the emergency physician integrated care, llc (epic) who staff ten-community hospital emergency departments (ed) in order to investigate physician knowledge and attitudes regarding cost and perceived patient compliance. in addition, a cross-sectional survey will be administered to a convenience sample of patients presenting to the university of utah emergency department to obtain information about their cost knowledge and reported compliance. all ed patients will complete a follow-up phone survey to measure compliance with recommendations made during the ed visits. following administration of the baseline survey physicians will be provided the prices of the test and procedures and will be re-surveyed 30-days later as a post intervention test to measure changes in knowledge and attitudes.


Eligibility criteria:
inclusion criteria patient population: * 18 years old or older * deemed psychologically and medically stable by the ed care provide * speak english exclusion criteria patient population: * prisoner * brought to emergency department by emergency medical service inclusion criteria physician population: * employed in target medical practices exclusion criteria physician population: * none

Keywords: attitudes of health personnel attitudes of patients medical compliance cost awareness cost analysis patient knowledge physician knowledge medical economics policy questionnaires health literacy
rijavithi viral and mycobacterium pcr arrays in cns infection study

Conditions: CNS Viral Infection

Summary: this study of neurotropic viral infection and tuberculous cns infection is the comprehensive investigation of csf pcr arrays (hybrydiaztion technique,sybergreen and taqman real time pcr arrays of csf ) in suspected cases of viral cns infection, tuberculous cns infection in both aids and non aids patients. patients with clinical viral encephalitis and all meningoencephalitis including all patients with hiv/aids csf and non aids will be banked and test for rna and dna viral sequence by real time pcr arrays and is6110 gene of mycobacterium tuberculosis. clinical data and final diagnosis will be used to analyze the result of this pcr arrays technique compared to clinical gold standard criteria.


Eligibility criteria:
inclusion criteria: 1. age more than 15 yrs 2. able to inform consent by themself or their parent 3. suspected cns viral infection exclusion criteria: 1. unable/contraindicated for lumbar puncture or csf collection 2. withdraw consent 3. suspected severe or vilurent viral infection such as h5n1/sars infection

Keywords: cns viral infection pcr hybridization
rapid on-site evaluation (rose) by endosonographer: for whom, when and by whom?

Conditions: Pancreatic Neoplasms

Summary: endoscopic ultrasound-guided fine-needle aspiration (eus-fna) is a highly sensitive and specific method in diagnosing solid pancreatic lesions. rapid on-site evaluation (rose) of the aspirate by a cytopathologist improves specimen adequacy and diagnostic accuracy while reducing the number of needle passes. as this increases costs and implicates availability issues, the investigators aimed to evaluate the utility of rose by the endosonographer in guiding eus-fna of solid pancreatic lesions.

consecutive patients with a solid pancreatic lesion were included. endosonographer was submitted to a basic pancreatic cythpatology training programme at two institutitions. the patients were randomly allocated to the rose group - in which the number of needle passes required to obtain a sample suitable for cytopathologic categorization was established by the endosonographer's on-site evaluation - or to the non-rose group - in whom adequacy of the specimen was evaluated macroscopically and up to five needle passes could be performed, assuring sample adequacy. the gold standard was the final cytopathologist's diagnosis. the number of needle passes, procedure duration, specimen adequacy, diagnostic yield and adverse events rates were compared between groups and the performance measures of rose by endosonographer were determined.

Eligibility criteria:
inclusion criteria: * solid pancreatic lesions detected by trans abdominal ultrasound or cross-sectional image (ct or mri). * formal indications to undergo eus-fna which were: differentiation between benign and malignant diseases, radiologic criteria of inoperability or unresectability, need for specific diagnosis which could modify therapeutic strategy and need for a diagnosis before neoadjuvant therapy. exclusion criteria: * a cystic or solid cystic aspect of the pancreatic lesion on above mentioned image methods * lesions previously punctured on past eus-fna procedures * american society of anesthesiologist (asa) physical status classification system iv or v * cases of surveillance of solid pancreatic lesions * severe coagulation disorder (platelet count \ 2,0) * impossibility of previous suspension of antiplatelet agents (except acetylsalicylic acid) or anticoagulants (all) * patient unwillingness to participate

Keywords: eus-fna pancreatic solid lesions sample adequacy cytopathology endosonography
gaps between evidence and practice in prevention of surgical site infection in spain

Conditions: Surgical Site Infection

Summary: web-based survey to members of 10 spanish associations of surgical nurses and surgeons of different specialities to know the application of preventative measures for surgical site infection.

a web-based survey to the members of the colorectal chapter of 10 spanish associations of surgical nurses and surgeons of different specialities. a link to the web page containing the survey will be disseminated via email, newsletter and twitter. a board from the surgical infection section did a review of evidence and previous guidelines to be used in the evaluation of the results. the most recent clinical practice guidelines have been analysed. according to the review, the preventive measures analysed in the survey have been distributed into two groups: high or low level of evidence. the survey aim to assess knowledge, beliefs, and practices of attending nurses and surgeons on preventative measures. furthermore, the questions address the level of accordance between their beliefs and the protocols or the usual practice of their units. the agreement rate between the beliefs and usual practice of all respondents will be calculated on a scale from 0 to 100. for discussion, the responses on the implementation of major surgical site infection (ssi) prevention measures will be compared with the recommendations of the expert group. the results will be expressed in percentages on the total answers obtained. responses will be entered into a computerized database that will be analysed using an specific program. the results will be analysed using the chi-square test with statistical significance defined as p \<0.05.

Eligibility criteria:
inclusion criteria: * nurses and surgeons pertaining to invited societies exclusion criteria: * none

Keywords: surgical site infection preventative measures
cardiac rehabilitation needs among individuals with atrial fibrillation

Conditions: Atrial Fibrillation (AF)

Summary: the goal of this survey- and registry-based study is to learn about the cardiac rehabilitation needs of individuals with atrial fibrillation (af). the main objectives of the study is to: 1. investigate cardiac rehabilitation needs among eligible individuals with af in a large af population 2. estimate how many needs referral to primary care programs, according to a needs assessment model.

atrial fibrillation (af) is the most common cardiac arrhythmia in adults globally. it poses significant public health challenges and is associated with substantial morbidity and mortality. af affects quality of life with an enlarged symptom burden. to improve life expectancy and quality of life, medical treatment along with risk factor management and cardiac rehabilitation is needed. in many countries, referral to cardiac rehabilitation remains low. furthermore, no guidelines or evidence provides details on whom should be referred. thus, we do not know how many individuals with af presents with cardiac rehabilitation needs. this study is a survey and registry-based study. danish health registries are used to draw a population of individuals with incident af in 2023-2024. following the exclusion criteria, these will receive a survey covering the described outcomes which are used to investigate needs of rehabilitation. a statistical predicitive analysis will be performed to estimate how many needs referral to cardiac rehabilitation.

Eligibility criteria:
inclusion criteria: * individuals with recidence in denmark, 18 years of age or above, with a cpr number (personal identification number) registered with a diagnosis of incident af in 2022 or 2023 (icd-10: di480\*). exclusion criteria: * death. * name- and address protection. * exemtion from using digital post. * living in a nursing home. * a diagnosis of dementia. * hospital admission or ambulant contacts due to mental illness within one year before diagnosis (except depression or anxiety). * individuals receiving palliative care or treatment.

Keywords: atrial fibrillation cardiac rehabilitation needs secondary prevention primary care survey registry
portal flow pulsatility as a risk factor for acute kidney injury after cardiac surgery

Conditions: C.Surgical Procedure; Cardiac; Acute Kidney Injury; Postoperative Complications; Right-Sided Heart Failure; Cardio-Renal Syndrome

Summary: the purpose of this study is to evaluate the possible association between portal vein flow pulsatility and acute kidney injury after cardiac surgery. participants will undergo assessment of portal vein flow and intra-renal blood flow using bedside doppler ultrasound before surgery and daily for three days after cardiac surgery.

acute kidney injury is a frequent complication after cardiac surgery. venous congestion from right ventricular dysfunction and fluid overload can impair kidney perfusion resulting in the cardio-renal syndrome. an increase in the variation of blood flow velocity in the portal vein during the cardiac cycle called portal pulsatility is a sign of congestive heart failure. portal pulsatility occurs when increased central venous pressure results liver venous congestion. the presence of abnormal portal pulsatility could be used as a marker of venous congestions in other organs such as the kidneys. discontinuous intra-renal vein flow is a risk factor for death or re-hospitalization in heart failure patients and could be seen in patients with portal pulsatility.

Eligibility criteria:
inclusion criteria: * 18 years and older. * undergoing cardiac surgery with the use of cardiopulmonary bypass * able to provide consent. exclusion criteria: * chronic renal replacement therapy before the procedure. * chronic kidney disease stage 5 defined as a estimated glomerular filtration rate by the mdrd equation (egfr-mdrd) of 15 ml/min/1,73m2 or less. * critical pre-operative state defined as aborted sudden death, preoperative cardiac massage, preoperative ventilation before anaesthetic room, preoperative inotropes or intra-aortic counterpulsation balloon. * patients previously diagnosed with a condition interfering with doppler evaluation of the portal system: portal vein thrombosis, cirrhosis. * patients with documented aki before surgery. * confirmed or suspected pregnancy. * kidney transplant recipients.

Keywords: ultrasonography portal vein doppler renal doppler cardio-intestinal syndrome delirium renal congestion intra-renal hemodynamics